©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
The Proto-oncogene Product c-Crk Associates with Insulin Receptor Substrate-1 and 4PS
MODULATION BY INSULIN GROWTH FACTOR-I (IGF) AND ENHANCED IGF-I SIGNALING (*)

(Received for publication, January 18, 1996)

Dana Beitner-Johnson (§) Vicky A. Blakesley Zila Shen-Orr Marce Jimenez Bethel Stannard Ling-Mei Wang (1) Jacalyn Pierce (1) Derek LeRoith (¶)

From the Diabetes Branch, NIDDK Laboratory of Cellular and Molecular Biology, NCI, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The Crk proto-oncogene product is an SH2 and SH3 domain-containing adaptor protein which we have previously shown to become rapidly tyrosine phosphorylated in response to stimulation with insulin-like growth factor I (IGF-I) in NIH-3T3 cells. In order to further characterize the role of Crk in the IGF-I signaling pathway, NIH-3T3 and 293 cells were stably transfected with an expression vector containing the Crk cDNA. The various resultant 3T3-Crk clones expressed Crk at approximately 2-15-fold higher levels than parental 3T3 cells. In 3T3-Crk cells, Crk immunoreactivity was detected in insulin receptor substrate-1 (IRS-1) immunoprecipitates. Stimulation with IGF-I resulted in a dissociation of Crk protein from IRS-1. In contrast, the association of the related adaptor protein Grb2 with IRS-1 was enhanced by IGF-I stimulation. Similar results were obtained in stably transfected 293-Crk cells, which express both IRS-1 and the IRS-1-related signaling protein 4PS. In these cells, IRS-1 and 4PS both associated with Crk, and this association was also decreased by IGF-I treatment, whereas the association of Grb2 with IRS-1 and 4PS was enhanced by IGF-I. Overexpression of Crk also enhanced IGF-I-induced mitogenesis of NIH-3T3 cells, as measured by [^3H]thymidine incorporation. The levels of IGF-I-induced mitogenesis were proportional to the level of Crk expression. These results suggest that Crk is a positive effector of IGF-I signaling, and may mediate its effects via interaction with IRS-1 and/or 4PS.


INTRODUCTION

The c-Crk protein is a cellular homolog of the viral oncogene v-crk product, an SH2 and SH3 domain-containing protein, encoded by the avian sarcoma virus CT10(1) . Crk proteins share homology with the adaptor proteins Grb2 and Nck(2, 3) , and are known to associate with two guanine nucleotide releasing proteins, C3G and mSos(4, 5) . These studies suggested that Crk may participate in growth factor-induced activation of Ras. In addition, we have recently shown that stimulation of IGF-I (^1)receptors results in rapid tyrosine phosphorylation of Crk(6) . Thus, it was of interest to further characterize mechanisms by which Crk could be involved in IGF-I receptor signaling pathways.

IRS-1 is a major phosphotyrosine substrate of the IGF-I and insulin receptors(7, 8, 9) . IRS-1 acts as a docking protein, associating through multiple phosphorylated tyrosine residues with various SH2 domain-containing proteins, including the p85 subunit of phosphatidylinositol 3-kinase(10, 11, 12, 13) , Grb2(14, 15, 16) , Syp(17, 18, 19) , and Nck(20) . 4PS (also termed IRS-2) is an IRS-1-related molecule that functions similarly in coupling the IL-4 receptor to intracellular signaling pathways (21) and can also partially mediate insulin signaling in IRS-1-deficient animals(22, 23) . Given that stimulation with IGF-I results in tyrosine phosphorylation of Crk (6) and the interaction of IRS-1 with the Crk-related molecules Grb2 and Nck, it was of interest to determine whether IRS-1 and 4PS also associate with Crk. In the present study we find that c-Crk associates with IRS-1 and 4PS and enhances IGF-I-induced mitogenesis.


MATERIALS AND METHODS

Cell Culture

Both human embryonic kidney carcinoma (293) cells and NIH-3T3 mouse fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM, Biofluids, Rockville, MD) supplemented with 10% fetal bovine serum (Upstate Biotechnology Inc., Lake Placid, NY). Prior to growth factor stimulation, subconfluent cultures of cells in 60- or 100-mm dishes were switched to serum-free DMEM supplemented with 0.1% insulin-free bovine serum albumin (Intergen, Purchase, NY) and 20 mM HEPES (pH 7.5), for 18 h. Cells were treated with IGF-I (Genentech, San Francisco, CA) diluted in serum-free DMEM at 37 °C for various time points and concentrations, as indicated.

Stable Transfections

Cells were stably transfected with either pCXN2-CRK II, a Crk expression vector driven by the cytomegalovirus promoter and carrying neo^r (kindly provided by M. Matsuda, Tokyo, Japan), or the pCXN2 vector from which the Crk cDNA had been excised. The Crk cDNA was excised from pCXN2-CRK II by cleavage with EcoRI and religation. Cells were transfected with 10 µg of either pCXN2-CRK II or the pCXN2 vector using the Lipofectamine reagent (Life Technologies, Inc., Gaithersburg, MD) according to the manufacturer's recommended conditions. Selection in 0.5 mg/ml G418 (Life Technologies, Inc., Gaithersburg, MD) began 48 h after transfection. After 2 to 3 weeks of selection in G418, individual colonies were isolated using 0.8-mm glass cloning cylinders (PGC Scientifics, Gaithersburg, MD).

Characterization of Resulting Clones

Clones were screened for Crk overexpression by immunoblotting for Crk as described below. Twenty-nine 3T3-Crk clones were obtained with Crk levels ranging from 2-15-fold overexpression, as compared to parental NIH 3T3 cells or 3T3-Neo cells (those transfected with the pCXN2 vector). Twelve 293-Crk clones were obtained with Crk levels ranging from 3-12-fold overexpression, as compared to parental 293 cells or 293-Neo cells, transfected with the pCXN2 vector. IGF-I receptor numbers in 3T3-Neo and 3T3-Crk cells were determined by Scatchard analysis using I-IGF-I as a tracer, as described previously(24) .

Immunoprecipitations

After treatment with growth factors, cells were washed twice with ice-cold phosphate-buffered saline and harvested in a lysis buffer containing 50 mM HEPES (pH 7.4), 2 mM sodium orthovanadate, 100 mM NaCl, 4 mM sodium pyrophosphate, 200 mM EDTA, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml aprotinin, and 1% Triton X-100. Lysates were incubated for 1 h at 4 °C, then centrifuged at 10,000 times g for 30 min at 4 °C to remove Triton-insoluble material. Protein content of the lysates was determined by the Bio-Rad method. 600 µg of protein from each dish was immunoprecipitated overnight at 4 °C with rabbit polyclonal antiserum (1:100) specific for either IRS-1 or 4PS(21, 25) , followed by adsorption to 50 µl of 10% Protein A-Sepharose beads (Pharmacia Biotech Inc.) for 5 h at 4 °C. Immunoprecipitates were washed 3 times with ice-cold immunoprecipitation buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 0.2 mM sodium orthovanadate, 1 mM EDTA, 1 mM EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, and 0.5% Nonidet P-40. The entire immunoprecipitated samples were then boiled for 2 min in sample buffer containing 50 mM Tris (pH 6.7), 2% SDS, 2% beta-mercaptoethanol, and bromphenol blue as a marker. Samples were then run on 9% SDS-PAGE gels and transferred to nitrocellulose membranes using standard electrophoresis and electroblotting procedures. Prestained molecular weight markers were obtained from Sigma (#SDS-7B).

Immunoblotting

Nitrocellulose membranes were blocked with either 3% insulin-free bovine serum albumin (for phosphotyrosine blotting) or 3% nonfat dry milk in a PBST buffer containing 10 mM sodium phosphate (pH 7.2), 140 mM NaCl, and 0.1% Tween 20. Blots were then immunolabeled overnight at 4 °C for phosphotyrosine (RC20H, 1:2500, Transduction Labs, Lexington, KY), Crk (1:1000, Transduction Labs, Lexington, KY), Grb2 (1:1000, Transduction Labs, Lexington, KY), IRS-1 (1:500)(25) or 4PS (1:500)(21) . Immunolabeling was detected by enhanced chemiluminescence (ECL, Amersham) according to the manufacturer's conditions. Some blots were stripped and re-probed with another antibody. Blots were stripped by incubation for 1 h at 50 °C in a solution containing 62.5 mM Tris-HCl (pH 6.7), 2% SDS, and 0.7% beta-mercaptoethanol. Blots were then washed for 1 h in several changes of PBST at room temperature, and probed with ECL to confirm that antibodies had been completely removed. Blots were then re-blocked and immunolabeled as described above.

Thymidine Incorporation Assays

Subconfluent cell monolayers in 12-well plates were grown to quiescence in serum-free DMEM with 0.1% bovine serum albumin for 24 h. Cells were then incubated for 16 h in DMEM containing 0.1% bovine serum albumin plus various concentrations of IGF-I. Each cell line was plated in triplicate for each concentration of IGF-I. The media was replaced with fresh serum-free DMEM containing 1 µCi/well of [^3H]thymidine, and the cells were incubated for an additional hour. The cells were rinsed twice with ice-cold phosphate-buffered saline, twice with ice-cold 5% trichloroacetic acid, and twice with ice-cold 95% ethanol. The cells were then lysed in 0.3 ml of 1 N NaOH, neutralized with 0.3 ml of 1 N HCl, and solubilized samples were counted by liquid scintillation.


RESULTS

NIH-3T3 cells were stably transfected with a Crk cDNA, as described. 3T3-Crk clones were selected in G418 and screened for Crk expression by immunoblot analysis. Out of 29 clones obtained, several clones were selected to use for further studies. As shown in Fig. 1A, two clones, 3T3-Crk7 and 3T3-Crk9, expressed 10- and 3-fold higher levels of Crk, respectively, than 3T3 parental or 3T3-Neo cells, as determined by densitometric scanning. These clones were chosen in order to evaluate the effects of relatively high levels of Crk expression (3T3-Crk7) and moderate levels of Crk expression (3T3-Crk9) on IGF-I action. Crk was also stably transfected into the 293 human embryonic kidney carcinoma cell line which, like NIH-3T3 cells, expresses endogenous IGF-I receptors. Interestingly, these cells also express relatively high levels of the IRS-1-like signaling protein 4PS, and IGF-I activates both IRS-1 and 4PS in this cell line (see below). Twelve 293-Crk clones were obtained after G418 selection, and several were selected for further study, including 293-Crk4 and 293-Crk6. These cell lines expressed 10-fold and 12-fold higher levels of Crk immmunoreactive protein, respectively, as compared to 293 parental cells (Fig. 1B).


Figure 1: Crk overexpression in NIH-3T3 and 293 cells. NIH-3T3 and 293 cells were stably transfected with an expression vector containing Crk cDNA as described under ``Materials and Methods.'' A, total lysates (10 µg) from parental NIH-3T3 cells (P), pCXN2-Neo transfected cells (N4 and N11 clones), or pCXN2-Crk transfected cells (C7 and C9 clones) were immunoblotted for Crk. B, total lysates (10 µg) from parental 293 cells (P), pCXN2-Neo transfected cells (N2 and N6 clones), or pCXN2-Crk transfected cells (C4 and C6 clones) were immunoblotted for Crk.



Serum-deprived 3T3-Crk7 cells were incubated for 5 min in the presence or absence of 100 nM IGF-I. Cleared whole cell lysates were immunoprecipitated with anti-IRS-1 serum and proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose as described. Using prestained molecular weight markers as a guide, blots were cut into three strips containing tyrosine-phosphorylated IRS-1 (180 kDa), Crk (40 kDa), or Grb2 (23 kDa). As shown in Fig. 2A, stimulation with IGF-I resulted in tyrosine phosphorylation of IRS-1. It can be seen in Fig. 2A that IRS-1 immunoprecipitates also contained Crk and Grb2 immunoreactivity. IGF-I increased the amount of Grb2 associated with IRS-1, in a manner similar to the effects of insulin on the association of the these molecules(14, 15) . Interestingly, IGF-I decreased the amount of Crk protein in IRS-1 immunoprecipitates. The 3T3-Crk7 clone shown in Fig. 2A expresses 10-fold higher levels of Crk than parental NIH-3T3 cells. As shown in Fig. 2B, association of IRS-1 with Crk was also detected in two independent clones that expressed lower levels of Crk, 3T3-Crk17 and 3T3-Crk 9. These clones express Crk at 8-fold and 3-fold higher levels, respectively, than in parental cells (data not shown). IGF-I also decreased the amount of Crk associated with IRS-1 in these cells (Fig. 2B).


Figure 2: Effect of IGF-I treatment on the interaction of Crk and Grb2 with IRS-1. A, 3T3-Crk7 cells were either unstimulated(-) or stimulated (+) with 100 nM IGF-I for 5 min. Lysates were immunoprecipitated with an anti-IRS-1 antiserum and run on a 9% SDS-PAGE gel. Immunoblots were cut into three sections and blotted as follows: 116-200 kDa range, phosphotyrosine (PY); 26-58 kDa (Crk); 0-26 kDa (Grb2). Each lane represents lysate prepared from an individual dish of 3T3-Crk7 cells. B, 3T3-Crk7 (lanes 5 and 6), 3T3-Crk17 (lanes 7 and 8) of 3T3-Crk9 (lanes 9 and 10) were either unstimulated(-) or stimulated (+) with 100 nM IGF-I for 5 min. Lysates were immunoprecipitated with IRS-1 antiserum and run on a 9% SDS-PAGE gel, and immunoblotted for Crk. The results shown are representative of those obtained in three separate experiments.



We found a similar Crk association with IRS-1 in 293-Crk6 cells. In this cell type, IGF-I induced tyrosine phosphorylation of IRS-1, and IRS-1 immunoprecipitates also contained Crk and Grb2 proteins (Fig. 3). Again, whereas Crk association with IRS-1 was markedly decreased by IGF-I, Grb2 association was enhanced. In addition to expressing IRS-1, 293 cells also express high levels of the IRS-1-related signaling protein, 4PS as determined by immunoblot analysis utilizing an anti-4PS serum that does not recognize IRS-1. (^2)IGF-I also induced tyrosine phosphorylation of 4PS (Fig. 3). Crk and Grb2 were detected in 4PS immunoprecipitates, and similarly, Crk association with 4PS was decreased by IGF-I stimulation, whereas Grb2 association was increased. Identical results were obtained with the 293-Crk4 clone (data not shown).


Figure 3: Effect of IGF-I on interaction of Crk and Grb2 with IRS-1 and 4PS. 293-Crk6 cells were either unstimulated (-) or stimulated (+) with 100 nM IGF-I for 5 min. Lysates were immunoprecipitated with either 4PS antiserum or IRS-1 antiserum and run on a 9% SDS-PAGE gel. Immunoblots were cut into three sections and blotted as follows: 116-200 kDa, phosphotyrosine (PY); 26-58 kDa (Crk); 0-26 kDa (Grb2). The results shown are representative of those obtained in three separate experiments.



We considered the possibility that overexpression of Crk could alter the level of IRS-1 or IGF-I receptor expression. In Fig. 4it can be seen that IRS-1 levels were not different in 3T3-Neo and 3T3-Crk cells, as measured by immunoblotting. We also found IGF-I receptor numbers to be equivalent in these cells, as measured by radioligand binding. Receptor numbers per cell were: 3T3-Neo4, 54,000; 3T3-Neo11, 67,000; 3T3-Crk7, 61,000; and 3T3-Crk9, 52,000.


Figure 4: IRS-1 expression in 3T3-Neo and 3T3-Crk cells. NIH-3T3 cells were stably transfected with either pCXN2-Crk (C7 and C9) or the pCXN2 vector from which the Crk cDNA had been excised (N4 and N11), as described. Lysates were immunoprecipitated with IRS-1 antiserum and run on a 9% SDS-PAGE gel, and immunoblotted for IRS-1. The results shown are representative of those obtained in three separate experiments.



In order to evaluate the functional effects of Crk overexpression on IGF-I signaling, the mitogenic effects of IGF-I were compared in two 3T3-Crk clones and two 3T3-Neo clones using a [^3H]thymidine incorporation assay. As shown in Fig. 5, 3T3-Crk7 and 3T3-Crk9 were significantly more responsive to IGF-I than were 3T3-Neo4 and 3T3-Neo11. While the 3T3-Crk7 exhibited the highest levels of IGF-I-induced thymidine incorporation, 3T3-Crk9 displayed intermediate levels, and the two 3T3-Neo cell lines had the lowest levels of thymidine incorporation. These findings are consistent with the levels of Crk expressed by these cell types, namely, 3T3-Crk7 > 3T3-Crk9 > 3T3-Crk-Neo (see Fig. 1).


Figure 5: Effect of Crk overexpression on IGF-I-induced mitogenesis. IGF-I stimulated thymidine incorporation. Subconfluent monolayers of cells were made quiescent in serum-free media for 24 h and then stimulated with the indicated concentration of IGF-I or 10% FBS for 16 h at 37 °C. [^3H]Thymidine (1 µCi/ml) was added and the incubation was continued for 1 h. Incorporated counts were measured as described under ``Materials and Methods.'' All assays were carried out in triplicate and the standard error for each cell line in individual experiments was within 5%. The data shown are a representative experiment that was performed three times. For each cell line, thymidine incorporation was normalized to 10% serum stimulation. Cell lines: 3T3-Neo4 (circle), 3T3-Neo11 (box), 3T3-Crk9 (), 3T3-Crk7 (bullet). The results obtained are representative of four separate experiments.




DISCUSSION

Very little is known about the role played by Crk in growth factor receptor signal transduction. These studies show that in two Crk overexpressing cell types, Crk interacts both with IRS-1 and with the IRS-1-related signaling molecule, 4PS. IRS-1 and 4PS function as multisite ``docking proteins'' which link insulin and IGF-I receptors as well as IL-4 receptors (9, 21, 25, 26) with various post-receptor signaling systems. The typical mechanism of such associations is via interaction of phosphotyrosine residues within the IRS-1 molecule with SH2 domains of other proteins(16) . The preferred phosphotyrosine recognition motif of the Crk SH2 domain is Y-X-X-P(27) , and both IRS-1 and 4PS contain several Y-X-X-P motifs(21, 28) . Thus, one possible mechanism of interaction of Crk with IRS-1 and 4PS is via interaction of the Crk SH2 domain with these phosphotyrosines. Another possible mechanism by which Crk could associate with IRS-1 and/or 4PS is by interaction of its SH3 domains with proline-rich sequences(29, 30) , such as those found in mSos and C3G(4) . IRS-1 contains a proline-rich potential SH3 binding domain in the C-terminal region of the protein(28) .

Interestingly, IGF-I induced a dissociation of Crk from IRS-1 and 4PS. This is in striking contrast to the effects of insulin and IGF-I on the association of IRS-1 with a number of other SH2 domain-containing proteins, including the adaptor protein Grb2(14, 15, 16, 21) , the adaptor protein Nck(20) , phosphatidylinositol 3-kinase(9, 10, 11, 12) , and the protein tyrosine phosphatase Syp(17, 18, 19) . These associations all occur weakly under basal conditions and become markedly enhanced by stimulation with insulin or IGF-I. The IGF-I-induced dissociation of Crk from IRS-1 and/or 4PS thus represents a novel mechanism in insulin and IGF-I signaling, namely, demonstrating that an SH2 domain-containing protein ``undocks'' from IRS-1 in response to growth factor stimulation. In addition, these findings are the first to report growth factor-induced modulation of the interaction of c-Crk with other proteins.

Previously, we have shown that stimulation of NIH-3T3 or 293 cells with IGF-I induces tyrosine phosphorylation of Crk(6) . This change in phosphorylation state may be related to Crk dissociation from the IRS-1 and 4PS molecules. It has been shown that there is an intramolecular interaction between the SH2 domain in Crk and a phosphotyrosine at residue 221(31) . This interaction suggests that pTyr-221 may compete with other phosphotyrosine residues (such as those in IRS-1 and 4PS) for binding to the Crk SH2 domain(30, 31) . Thus, tyrosine phosphorylation of Crk by the IGF-I receptor may result in intramolecular association of pTyr-221 with the Crk SH2 domain and promote dissociation from IRS-1 and 4PS. A similar mechanism has been proposed for the phosphorylation-induced dissociation of Crk from c-Abl (30) . In analogy with these studies, a phosphotyrosine/SH2 interaction would appear likely as the basis of IRS-1/Crk association. However, further studies will be needed to test this hypothesis.

In functional assays, we show that overexpression of Crk enhances IGF-I-induced mitogenesis in NIH-3T3 cells. Furthermore, the degree of IGF-I-stimulated growth was proportional to the level of Crk protein expression in these cells. Taken together, the data strongly suggest that Crk is a positive effector of IGF-I signaling, and that this occurs, at least in part, via interaction of the Crk protein with IRS-1 and/or 4PS. At this point, it remains uncertain whether it is Crk/IRS-1 association or dissociation that is a key event in IGF-I signaling. It will be of interest in further studies to determine the precise mechanism of interaction of these molecules, and to delineate the intracellular pathways by which Crk is involved in IGF-I induced mitogenesis.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Dept. of Cellular and Molecular Physiology, College of Medicine, University of Cincinnati, Cincinnati, OH 45267-0576.

To whom correspondence should be addressed: Bldg. 10, Rm. 8S-235A, 10 Center Dr., MSC 1770, Bethesda, MD 20892-1770. Tel.: 301-496-8090; Fax: 301-480-4386.

(^1)
The abbreviations used are: IGF-I, insulin-like growth factor-I; IRS-1, insulin receptor substrate-1; DMEM, Dulbecco's modified Eagle's medium; PAGE, polyacrylamide gel electrophoresis; SH2 and SH3, Src homology regions 2 and 3, respectively.

(^2)
D. Beitner-Johnson, V. A. Blakesley, Z. Shen-Orr, M. Jimenez, B. Stannard, L-M. Wang, J. Pierce, and D. LeRoith, unpublished observations.


ACKNOWLEDGEMENTS

We thank Dr. Domenico Accili for his review and criticism of the manuscript.


REFERENCES

  1. Mayer, B. J., Hamaguchi, M., and Hanafusa, H. (1988) Nature 332, 272-275 [CrossRef][Medline] [Order article via Infotrieve]
  2. Reichman, C. T., Mayer, B. J., Keshau, S., and Hanafusa, H. (1992) Cell Growth & Differ. 3, 451-460
  3. Matsuda, M., Tanaka, S., Nagata, S., Kojima, A., Kurata, T., and Shibuya, M. (1992) Mol. Cell. Biol. 12, 3482-3489 [Abstract]
  4. Tanaka, S., Morishita, T., Hashimoto, Y., Hattori, S., Nakamura, S., Masabumi, S., Matuoka, K., Takenawa, T., Kurata, T., Nagashima, K., and Matsuda, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3443-3447 [Abstract]
  5. Matsuda, M., Hashimoto, Y., Moroya, K., Hasegawa, H., Kurata, T., Tanaka, S., Nakamura, S., and Hattori, S. (1994) Mol. Cell. Biol. 14, 5495-5500 [Abstract]
  6. Beitner-Johnson, D., and LeRoith, D. (1995) J. Biol. Chem. 270, 5187-5190 [Abstract/Free Full Text]
  7. White, M. F., Maron, R., and Kahn, C. R. (1985) Nature 318, 183-186 [Medline] [Order article via Infotrieve]
  8. Shemer, J., Adamo, M., Wilson, G. L., Heffez, D., Zick, Y., and LeRoith, D. (1987) J. Biol. Chem. 262, 15476-15482 [Abstract/Free Full Text]
  9. Myers, M. G., Jr., and White, M. (1993) Diabetes 42, 643-650 [Abstract]
  10. Backer, J. M., Myers, M. G., Jr., Shoelson, S. E., Chin, D. J., Sun, X.-J., Miralpeix, M., Hu, P., Margolis, B., Skolnick, E. Y., Schlessinger, J., and White, M. F. (1992) EMBO J. 11, 3469-3479 [Abstract]
  11. Myers, M. G., Jr., Backer, J. M., Sun, X.-J., Shoelson, S., Hu, P., Schlessinger, J., and White, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10350-10354 [Abstract]
  12. Yamamoto, K., Lapetina, E. G., and Moxham, C. P. (1992) Endocrinology 130, 1490-1498 [Abstract]
  13. Myers, M. G., Jr., Sun, X. J., Cheatham, B., Jachna, B. R., Glasheen, E. M., Backer, J. M., and White, M. (1993) Endocrinology 132, 1421-1430 [Abstract]
  14. Baltensperger, K., Kozma, L. M., Cherniack, A. D., Klarlund, J. K., Chawla, A., Banerjee, U., and Czech, M. (1993) Science 260, 1950-1952 [Medline] [Order article via Infotrieve]
  15. Skolnick, E. Y., Batzer, A., Lee, C. H., Lowenstein, E., Mohammadi, M., Margolis, B., and Schlessinger, J. (1993) Science 260, 1953-1955 [Medline] [Order article via Infotrieve]
  16. Sun, X.-J., Crimmins, D. L., Myers, M. G., Miralpeix, M., and White, M. F (1993) Mol. Cell. Biol. 13, 7418-7428 [Abstract]
  17. Kuhne, M. R., Pawson, T., Lienhard, G. E., and Feng, G.-S. (1994) J. Biol. Chem. 268, 11479-11481 [Abstract/Free Full Text]
  18. Case, R. D., Piccione, E., Wolf, G., Benett, A. M., Lechleider, R. J., Neel, B. G., and Shoelson, S. E. (1994) J. Biol. Chem. 269, 10467-10474 [Abstract/Free Full Text]
  19. Li, W., Nishimura, R., Kashishian, A., Batzer, A. G., Kim, W. J. H., Cooper, J. A., and Schlessinger, J. (1994) Mol. Cell Biol. 14, 509-517 [Abstract]
  20. Lee, C.-H., Li, W., Nishimura, R., Zhou, M., Batzer, A. G., Myers, M. G., White, M. F., Schlessinger, J., and Skolnick, E. Y. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11713-11717 [Abstract]
  21. Sun, X. J., Wang, L-M., Zhang, Y., Yenush, L., Myers, M. G., Glasheen, E., Wolf, G., Shoelson, S. E., Lane, W. S., Pierce, J. H., and White, M. F. (1995) Nature 377, 173-177 [CrossRef][Medline] [Order article via Infotrieve]
  22. Tamemoto, H., Kadowaki, T., Tobe, K., Yagi, T., Sakura, H., Hayakawa, T., Terauchi, Y., Ueki, K., Kaburagi, Y., Satoh, S., Sekihara, H., Yoshioka, S., Horikoshi, H., Furuta, Y., Ikawa, Y., Kasuga, M., Yazaki, Y., and Aizawa, S. (1994) Nature 372, 182-186 [CrossRef][Medline] [Order article via Infotrieve]
  23. Araki, E., Lipes, M. A., Patti, M.-E., Bruning, J. C., Haag, B., Johnson, R. S., and Kahn, C. R. (1994) Nature 372, 186-190 [CrossRef][Medline] [Order article via Infotrieve]
  24. Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., Jr., and LeRoith, D. (1993) J. Biol. Chem. 268, 2655-2661 [Abstract/Free Full Text]
  25. Wang, L.-M., Myers, M. G., Sun, X-J., Aaronson, S. A., White, M., and Pierce, J. H. (1993) Science 261, 1591-1594 [Medline] [Order article via Infotrieve]
  26. Wang, L.-M., Keegan, A. D., Li, W., Lienhard, G. E., Pacini, S., Gutkind, J. S., White, M. F., Aaronson, S. A., Paul, W. E., and Pierce, J. H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 4032-4036 [Abstract]
  27. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993) Cell 72, 767-778 [Medline] [Order article via Infotrieve]
  28. Araki, E., Sun, S.-J., Haag, B. L., III, Chuang, L.-M., Zhang, Z., Yang-Feng, T. L., White, M. F., and Kahn, C. R. (1993) Diabetes 42, 1041-1054 [Abstract]
  29. Ren, R., Mayer, B. J., Cicchetti, P., and Baltimore, D. (1993) Science 259, 1157-1161 [Medline] [Order article via Infotrieve]
  30. Feller, S. M., Ren, R., Hanafusa, H., and Baltimore, D. (1994) Trends Biochem. Sci. 19, 453-458 [CrossRef][Medline] [Order article via Infotrieve]
  31. Rosen, M. K., Yamazaki, T., Gish, G. D., Day, C. M., Pawson, T., and Kay, L. E. (1995) Nature 374, 477-479 [CrossRef][Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.